Gilead Sciences Presents New Data Reinforcing HIV Treatment and COVID-19 Research at IDWeek 2023

Gilead Sciences, a leading biopharmaceutical company, is set to present new data at IDWeek 2023, a prestigious conference held in Boston. The data highlights Gilead’s commitment to addressing the unmet medical needs of individuals affected by HIV and COVID-19. With 16 abstracts to be presented, Gilead aims to showcase its ongoing efforts in virology research and development.

The HIV research presented at IDWeek 2023 will demonstrate Gilead’s dedication to advancing innovation in HIV treatment and prevention. The studies will include real-world evidence from the ongoing BICSTaR study, which assesses the long-term efficacy and safety of Biktarvy, a complete HIV treatment. Additionally, retrospective observational studies will explore the effectiveness and safety of Biktarvy in individuals with suboptimal adherence to oral antiretroviral therapy and those with pre-existing drug resistance.

Gilead will also present data on lenacapavir, a first-in-class, long-acting HIV-1 capsid inhibitor. This includes two-year results from the CAPELLA study, which evaluates the antiviral activity and safety of lenacapavir administered as a subcutaneous injection in heavily treatment-experienced individuals with multi-drug resistant HIV. The research will also focus on alternative subcutaneous administration sites for lenacapavir.

In the realm of HIV prevention, Gilead will present results from a study examining the real-world impact of pre-exposure prophylaxis (PrEP) access and dispensing status on the likelihood of acquiring HIV. Another study will explore the increase in new HIV cases among individuals who could benefit from PrEP during the COVID-19 pandemic.

Regarding COVID-19 research, Gilead will reinforce the strong safety profile and in vitro activity of Veklury, its antiviral standard of care for hospitalized patients with COVID-19. The data will demonstrate Veklury’s continued effectiveness against new variants, including the Omicron subvariants. Gilead will also present studies on the safety of Veklury in vulnerable populations and resistance analyses in patients with reduced kidney function.

As part of its commitment to addressing the unmet needs of COVID-19 patients, Gilead will present research on obeldesivir, an investigational oral antiviral. The studies will analyze potential drug-drug interactions and obeldesivir’s antiviral activity against recent Omicron subvariants.

Gilead’s participation in IDWeek 2023 reflects its dedication to advancing virology research and development. By sharing these latest findings, Gilead aims to contribute to the future of HIV clinical care and the ongoing fight against COVID-19.

For more information about Gilead’s presentations at IDWeek 2023, including a complete list of abstracts, please visit the conference’s official website.